Tag: Rezdiffra

With a wholesale acquisition cost of approximately $47,400 per year, Rezdiffra's price point has drawn significant attention. The question 'Why is Rezdiffra so expensive?' is answered by several factors, including its status as the first-in-class treatment for MASH, extensive research and development costs, and market exclusivity.

Rezdiffra (resmetirom) is the first FDA-approved medication specifically for metabolic dysfunction–associated steatohepatitis (MASH), a form of fatty liver disease, with moderate to advanced liver scarring. While a promising therapy, it is crucial to understand **what are the side effects of Rezdiffra for fatty liver** to manage treatment effectively and safely.

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved medication specifically for noncirrhotic non-alcoholic steatohepatitis (NASH), now known as MASH. This landmark approval was a significant development for patients and healthcare providers, yet it has raised a critical question: is there a generic for Rezdiffra? The short answer is no, and its status as a brand-name-only medication is tied to complex legal and commercial factors.

Following its FDA accelerated approval in March 2024, Rezdiffra™ (resmetirom) became the first and only medication specifically approved for treating noncirrhotic nonalcoholic steatohepatitis (NASH). As a specialized treatment, Rezdiffra™ is not available at standard retail pharmacies, and obtaining it requires a specific process involving a prescription and a network of specialty pharmacies.

According to the American Liver Foundation, metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease, affects millions of Americans and is a leading cause of liver-related illness and mortality. Finding an effective answer to the question, "What drug is used to reverse fatty liver?" has been a long-standing challenge, but recent FDA approvals represent a major breakthrough in treatment options.

In 2024, the U.S. Food and Drug Administration (FDA) approved the first-ever drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver disease. A **MASH drug** is a medication specifically designed to treat this condition, which is characterized by fat buildup, inflammation, and scarring in the liver. The approval of these specialized treatments marks a significant advancement for millions affected by this progressive disease, who previously had limited therapeutic options.

Affecting up to one-third of adults, fatty liver disease is a common condition with potentially serious consequences. For individuals with advanced forms like metabolic dysfunction-associated steatohepatitis (MASH), the question of what drug gets rid of a fatty liver is becoming a reality as new medications emerge alongside traditional lifestyle interventions.